Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W6CA
|
|||
| Former ID |
DAP000457
|
|||
| Drug Name |
Cefpodoxime
|
|||
| Synonyms |
CPDX; Cefpodoxima; Cefpodoximum; Epoxim; Cefpodoxim acid; Cefpodoxima [Spanish]; Cefpodoximum [Latin]; RU 51807; Cefpodoxime (INN); Cefpodoxime [INN:BAN]; Epoxim (TN); Vantin (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1] | |
| Therapeutic Class |
Antibiotics
|
|||
| Company |
Pfizer Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H17N5O6S2
|
|||
| Canonical SMILES |
COCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O
|
|||
| InChI |
1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
|
|||
| InChIKey |
WYUSVOMTXWRGEK-HBWVYFAYSA-N
|
|||
| CAS Number |
CAS 80210-62-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10314, 7978883, 14832042, 14880676, 23947634, 42980683, 46504897, 48415725, 49835234, 51091954, 79167407, 87305645, 96099266, 103639168, 104133802, 114466102, 124766016, 134337752, 135013061, 137002897, 138999736, 140396441, 160964685, 163409420, 163847698, 175268415, 179151199, 196378890, 226414761, 241157558, 252347160
|
|||
| ChEBI ID |
CHEBI:3504
|
|||
| ADReCS Drug ID | BADD_D00395 | |||
| SuperDrug ATC ID |
J01DD13
|
|||
| SuperDrug CAS ID |
cas=080210624
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacillales | ||||
|
Studied Microbe: Staphylococcus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Staphylococcus was increased by Cefpodoxime proxetil. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bifidobacterium was decreased by Cefpodoxime proxetil. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Enterobacteria
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterobacteria was decreased by Cefpodoxime proxetil. | |||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterobacteriaceae was decreased by Cefpodoxime proxetil. | |||
|
Studied Microbe: Escherichia
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Escherichia was decreased by Cefpodoxime proxetil. | |||
|
Studied Microbe: Klebsiella
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Klebsiella was decreased by Cefpodoxime proxetil. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Clostridium
Show/Hide Hierarchy
|
[2], [3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Clostridium was decreased by Cefpodoxime proxetil. | |||
|
Studied Microbe: Clostridium difficile
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Clostridium difficile was increased by Cefpodoxime proxetil. | |||
|
Studied Microbe: Eubacterium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Eubacterium was decreased by Cefpodoxime proxetil. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterococcus was increased by Cefpodoxime proxetil. | |||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterococcus was increased by Cefpodoxime proxetil. | |||
|
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Lactobacillus was decreased by Cefpodoxime proxetil. | |||
|
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Streptococcus was decreased by Cefpodoxime proxetil. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
|
Studied Microbe: Veillonella
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Veillonella was not significantly changed by Cefpodoxime proxetil. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Penicillin binding protein (Bact PBP) | Target Info | Binder | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 2 | Impact of cefpodoxime proxetil and amoxicillin on the normal oral and intestinal microflora. Eur J Clin Microbiol Infect Dis. 1993 Sep;12(9):714-9. | |||
| REF 3 | The relationship between an increase in beta-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances. J Antimicrob Chemother. 1994 Jul;34(1):127-38. | |||
| REF 4 | Betalactam therapy and intestinal flora. J Chemother. 1995 May;7 Suppl 1:25-31. | |||
| REF 5 | Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.